Company intelligence / Profile preview
Amneal Pharmaceuticals, Inc.
- Ownership
- Public · AMRX
- Employees
- ~8000
- Development stage
- Other
Overview
Amneal has a diverse portfolio of over 280 generic and specialty pharmaceuticals. The company has 3 FDA-approved biosimilars in the market with more in development. They focus on complex generics, specialty products, oncology biosimilars, and institutional injectables.
- Therapeutic areas
- Neurology
- Modalities
- Generic pharmaceuticalsSpecialty pharmaceuticalsBiosimilarsInjectables
- Industry
- Biotech
Drug pipeline
23 assets22 more assets in the full pipeline.
Financials
- Market cap
- $6.8B
- Total revenue
- $3B
- Enterprise value
- $9.9B
Beyond the preview
Go deeper on Amneal Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amneal Pharmaceuticals, Inc..